Biotechnology Company Founded on Weill Cornell Technology Announced $90 Million Series A Financing to Advance Radioantibody Treatment for Cancer

Convergent Therapeutics Inc., a clinical-stage biotechnology company co-founded by Dr. Neil Bander, the Bernard and Josephine Chaus Professor of Urologic Oncology, announced May 3 the completion of a $90 million Series A financing. Convergent focuses on developing next-generation radiopharmaceuticals for the treatment of cancer. The financing will support its development of a pipeline of novel radioantibodies, including its lead program with CONV01-α, for the treatment of advanced prostate cancer.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see profile for Dr. Neil Bander.